Ιατρικά Άρθρα: SHR-1210 in Recurrent/Metastatic Nasopharyngeal Carcinoma Who Have Received Previous At Least Two Lines of Chemotherapy.

Παρασκευή 15 Ιουνίου 2018

SHR-1210 in Recurrent/Metastatic Nasopharyngeal Carcinoma Who Have Received Previous At Least Two Lines of Chemotherapy.

Condition: Nasopharyngeal Carcinoma
Intervention: Drug: SHR-1210
Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Not yet recruiting

https://ift.tt/2takPxf

Ιατρικά Άρθρα

Ετικέτες

Παρασκευή 15 Ιουνίου 2018

SHR-1210 in Recurrent/Metastatic Nasopharyngeal Carcinoma Who Have Received Previous At Least Two Lines of Chemotherapy.

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου

Multifunctional Two-Dimensional Bi<sub>2</sub>Se<sub>3</sub> Nanodiscs for Anti-Inflammatory Therapy of Inflammatory Bowel Diseases

Αναζήτηση αυτού του ιστολογίου

Αναφορά κατάχρησης